Genomics and Epigenomics for New Insights in fEmale OAB (GENIE) Study (GENIE)
Epigenomics in Insulin Resistance Associated Overactive Bladder.
Millions of women suffer from overactive bladder, and the changes in bladder function affect their quality of life. The study team believes that it needs to be better understand why women get overactive bladder in the first place so that better treatments can eventually be offered.
The purpose of this study is to determine why women with insulin resistance are more likely to get overactive bladder. Overactive bladder is a type of bladder control problem that can cause some women to have bladder leakage. This problem is more common in women with diabetes and pre-diabetes, but it isn't known why.
調査の概要
詳細な説明
The methylation of cytosines in CpG sites can have profound effects on the ability of genes to be transcribed. To clarify and distinguish the specific methylation changes responsible for overactive bladder (OAB) in those with insulin resistance (IR), the investigator will compare three well-characterized groups of women: 1) OAB and IR; 2) IR only (no OAB); and 3) OAB only (no IR). In this proposal the investigator is only studying women since they are more likely to be affected by OAB with incontinence, the investigator wants to study pure cohorts of patients, and because this is the clinical population cared for by the primary investigator. The plan for future investigations is to apply these findings to broader groups to better understand gender and racial differences.
In Specific Aim 1, the investigator will conduct an epigenome-wide association study (EWAS) study, followed by targeted validation studies to determine whether CpG sites throughout the genome are differentially methylated in well-characterized and matched cohorts, while controlling for the effects of insulin-resistance. In Specific Aim 2, the investigator will assess for differential expression of candidate loci in relation to methylation. RNA-sequencing (RNA-seq) will be used to establish differences in the transcriptome between extreme phenotypes of OAB+IR and OAB alone. The investigator will then use quantitative polymerase chain reaction (qPCR) to validate expression differences in all cohorts, and to confirm differences in candidate loci that are confirmed in experiments from Aim 1. The investigator will proceed with bioinformatic pathway analyses to identify the function and interdependence of genes with altered expression and altered methylation profiles. In Specific Aim 3, the investigator will determine whether expression (mRNA and protein) differences in voided urine cells are also exhibited in biopsied bladder mucosa. The investigator will use targeted assays to confirm similar methylation profiles and gene expression in voided cells and bladder biopsies. The investigator will also compare protein expression of candidate loci such as EXOC6, ZFC3H1, RPS6KA2, and SPON2 proteins, if confirmed in other Aims, between cohorts. When the proposed studies have been completed, it is the expectation that the investigator will have functionally characterized the methylation changes that the investigator preliminarily identified in IR associated OAB.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27707
- Duke University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion criteria:
- Women over the age of 18.
- Urgency incontinence (at least 3 times per week) for > 3months
- History of elevated A1C or Type II diabetes (UUI+IR and IR only groups)
- Non-pregnant
- At least 6 months since most recent childbirth
Exclusion criteria:
- Active pregnancy, or within 6 months of childbirth
- Breastfeeding
- Proteinuria (defined as >1+ protein on urine dipstick in the absence of infection)
- Gross hematuria (in the absence of UTI)
- Type I diabetes mellitus
- Type II diabetes with chronic renal impairment (Cr >1.5)
- Chronic renal disease (includes vasculitis, focal segmental glomerulosclerosis, lupus nephritis, polycystic kidney disease, nephropathy)
- Receiving chemotherapy or radiation for malignancy
- Taking one of the following drugs that influence DNA methylation: hydralazine, procainamide, methotrexate, valproic acid, tamoxifen, raloxifene, letrozole, anastrozole (Arimidex), or exemestane (Aromasin)
- Any history of urinary tract malignancy (bladder, urethra, ureter, kidney)
- Intradetrusor Botox injection within the prior 12 months
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
---|
4
健康ボランティア
|
1
Women with Urgency Incontinence (At least three times per week) greater than three months, and without insulin resistance.
|
2
Women with insulin resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
|
3
Women with both UUI (at least three times per week for over three months) and Insulin Resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Proportions of differentially methylated CpG sites between cohorts, from Illumina EPIC chip
時間枠:2 years
|
Extract DNA from voided urine cells and compare human DNA using Illumina EPIC Methylation Chip to assess methylation of different sites across the genome
|
2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Compare methylation between DNA extracted from voided urine cells and bladder urothelial biopsies
時間枠:2 years
|
DNA will be extracted from voided urine cells and from urothelial biopsies in the same patients.
Targeted methylation assays will be used to compare methylation sites between sample types
|
2 years
|
Gene expression (from RNA-sequencing)
時間枠:2 Years
|
Compare mRNA recovered from bladder biopsies between women in 3 cohorts (Urgency incontinence only, insulin resistance only, urgency incontinence with insulin resistance)
|
2 Years
|
Gene expression (from PCR)
時間枠:2 Years
|
Compare expression of candidate genes between cohorts by using polymerase chain reaction (PCR) and extracted RNA
|
2 Years
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Nazema Y Siddiqui, MD、Duke University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。